Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection

January 12, 2024 updated by: Hong Wu, West China Hospital

Application of Indocyanine Green(ICG)@Human Serum Albumin(HSA) Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection: A Prospective, Double-Blinded, Randomized Controlled Trial

This study is a single-center, prospective, randomized controlled trial that aims to compare the efficacy and safety of a new indocyanine green (ICG) administration protocol with the current guideline-recommended protocol for near-infrared (NIR) fluorescence imaging in laparoscopic anatomical hepatic resection. Primary liver cancer is a common malignancy worldwide. Laparoscopic liver resection has become increasingly popular due to its minimally invasive nature. During open and laparoscopic liver resection surgery, ICG, a fluorescent dye, is widely used to visualize liver segments and define tumor margins. However, there is a lack of high-level evidence regarding the timing and dosage of ICG administration in current protocols. In our preliminary study, we discovered a new method of pre-mixing ICG with albumin, which creates a more stable conjugate that could enhance fluorescence imaging during NIR laparoscopic hepatectomy. This study will include 100 patients with primary liver malignancies who are scheduled for laparoscopic anatomical hepatic resection. The patients will be randomly assigned in a 1:1 ratio to either the new ICG-albumin protocol (experimental group) or the standard ICG alone protocol (control group). The primary outcome will be the efficacy of fluorescence imaging, which will be evaluated using a 5-point scoring system by three independent experts. Secondary outcomes will include operation time, blood loss, tumor margin status, complications, length of stay, long-term recurrence, and survival.

The hypothesis of this study is that pre-binding ICG with albumin creates a more stabilized fluorescent complex, which could significantly improve the efficacy of fluorescence navigation and hepatectomy outcomes compared to standard ICG alone. This study aims to provide high-quality evidence on optimal protocols for ICG use in laparoscopic fluorescent image-guided liver surgery. The results of this study could help establish standardized guidelines to improve the application of this important navigation technique and enhance surgical precision and outcomes for liver cancer patients worldwide. The study protocol will be approved by the Ethics Review Board and publicly registered before enrollment starts. All participants will be required to provide informed consent. This study will be conducted in compliance with the Declaration of Helsinki and national regulations on human subject protection to ensure ethics, privacy, and safety.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

  1. Study Design:

    This study is designed as a single center, prospective, randomized, double-blinded, controlled trial. The participants will be randomly assigned to either the experimental group (using the new ICG-albumin protocol) or the control group (using the standard ICG protocol) at a 1:1 ratio. The randomization will be done using a centralized web-based system.

  2. Participants:

    The study aims to enroll 100 patients aged 18-75 years old with primary liver malignancies who are planned for laparoscopic anatomical hepatic resection at our institution. The main inclusion criteria are a Child-Pugh grade A or B liver function and an ECOG performance score of 0-1. The main exclusion criteria include an ICG R15 value of >=20%, coagulation disorders, severe heart/lung disease, active bleeding, allergy to ICG, severe gastroesophageal varices, and pregnancy/lactation.

  3. Interventions:

    The interventions in the experimental group will involve mixing 0.5mg of ICG powder with 20mL saline containing 500mg of human albumin for at least 5 minutes. This mixture will then be intravenously infused at a rate of 1mL/min after occlusion of the target hepatic pedicles. On the other hand, the control group will receive a slow intravenous infusion of 2.5mg ICG (2.5mg/mL) following the current guidelines after pedicle occlusion.

  4. Outcomes:

    The primary outcome is the efficacy of fluorescence imaging, which will be evaluated by a 5-point scoring system by three independent experts. Secondary outcomes include operation time, blood loss, conversion to open surgery, parenchymal transection time, use of hemostatic clips, tumor margins, postoperative complications, liver function recovery, length of stay, long-term recurrence and survival. Safety outcomes include complications, mortality, and adverse reactions associated with ICG.

  5. Participant Timeline:

    Screening will take place within 2 weeks before surgery. Participants will be followed up during hospitalization. After discharge, follow-up will take place at month 1, 3, 6, 12, 18, 24, 30, 36 post-surgery.

  6. Sample Size:

    With a two-sided 0.05 significance level, 90% power, and expecting a 1-point improvement in fluorescence imaging efficacy score (SD 1.5), 49 participants per group are needed, 100 in total.

  7. Data Collection and Management:

    All data will be collected on paper case report forms and then entered into a centralized electronic data capture system. Data will go through quality check, cleaning, coding and logic validation. Any changes will be tracked. Cleaned and locked database will be used for final analysis. Original forms will be archived securely.

  8. Statistical Analysis :

    Efficacy of fluorescence imaging will be compared between groups using t-test or Mann-Whitney U test. Operation parameters will be analyzed by t-test or Wilcoxon rank test. Tumor margins will be evaluated by chi-square test. Complication rates will be compared using t-test or Fisher's exact test. Survival outcomes will be depicted by Kaplan-Meier curves and compared by Log-rank tests. Multivariate Cox regression will be used to identify factors affecting recurrence and survival. Sensitivity analysis will be performed to account for missing data.

  9. Data Monitoring:

    An independent data safety monitoring board will review study progress and safety data regularly. Any serious adverse events will be reported to investigators, IRB and regulatory agencies within 24 hours.

  10. Ethics and Dissemination and Trial Status:

The study protocol will be approved by the IRB before initiation. All participants will provide written informed consent. Results will be disseminated through scientific conferences and peer-reviewed publications. The study is currently preparing for ethics submission and enrollment is expected to start in December 2023 and complete in November 2026.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Sichuan
      • Chendu, Sichuan, China, 614000
        • Recruiting
        • West China Hospital
        • Contact:
        • Principal Investigator:
          • Qingyun Xie, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age: 18-75 years old, patients with hepatic malignancies who are undergoing laparoscopic anatomical liver resection;
  2. Preoperative liver function Child-Pugh grade A or B;
  3. No contraindications for laparoscopic liver resection;
  4. Expected survival ≥3 months;
  5. ECOG PS score 0-1;
  6. Normal major organ functions, and meet the following laboratory test results within 7 days prior to enrollment: white blood cell (WBC) ≥2.5×10^9/L, absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet (PLT) ≥75×10^9/L, hemoglobin (HGB) ≥90g/L; NR ≤1.5xULN; serum creatinine (CT) ≤1.5xULN; total bilirubin (TBI) ≤1.5×upper limit of normal (ULN);
  7. Patients voluntarily participate and sign informed consent.

Exclusion Criteria:

  1. No obvious ischemic demarcation line after intraoperative occlusion or disconnection of target hepatic pedicle, or the liver fluorescence reaches an intensity that interferes with surgery before intraoperative ICG injection.
  2. Poor hepatic reserve function (ICG R15 ≥ 20%);
  3. Severe cardiopulmonary diseases, intolerant to general anesthesia and surgery;
  4. Moderate or large amount of symptomatic ascites or pleural effusion;
  5. Active bleeding or coagulation abnormalities;
  6. Hepatic encephalopathy;
  7. Allergy to ICG;
  8. History of gastrointestinal bleeding within the past 6 months or definite tendency for gastrointestinal bleeding;
  9. Severe esophageal gastric varices requiring interventional treatment;
  10. Objective evidence showing severe impaired pulmonary function such as pulmonary fibrosis;
  11. Any significant clinical and laboratory abnormalities that the investigator considers affecting safety assessment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: The new ICG & HSA injection Group (experimental group)
After ligation of the targeted hepatic segmental portal vein, a novel ICG protocol is used (0.5mg ICG powder is added to 20mL normal saline containing 500mg human albumin, shaken and allowed to stand for more than 5 minutes to form a stable complex, with final concentrations of ICG 0.025mg/mL and human albumin 25mg/mL). This ICG-albumin conjugate solution is then administered intravenously at a rate of 1mL/min. The infusion is stopped when sufficient fluorescence enhancement is observed in the negative-staining liver regions.
Procedure: NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration
After ligation of the target hepatic segmental portal vein, the novel ICG regimen (0.5 mg ICG powder and 500 mg human serum albumin added to 20 ml saline, shaken and allowed to stand for more than 5 minutes, ICG: 0.025 mg/ml, human serum albumin: 25 mg/ml) was intravenously infused continuously at a rate of 1 ml/min until significant fluorescence imaging appeared in the demarcated area, upon which the infusion was terminated.
Active Comparator: The guideline-recommended ICG injection Group (active comparator group)
After ligation of the targeted hepatic segmental portal vein, 2.5mg of ICG (concentration 2.5mg/mL) is administered intravenously as a bolus injection.
Procedure: NIF image-guided laparoscopic anatomical liver resection with the guideline-recommended ICG administration
After ligation of the target hepatic segmental portal vein, 2.5 mg of ICG (2.5 mg/ml) was intravenously injected.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fluorescence imaging effect of the live
Time Frame: On the 7th day after surgery
The entire surgical video was recorded and then scored by experts
On the 7th day after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of surgery
Time Frame: At the end of the surgery
Based on the duration of the surgery as recorded
At the end of the surgery
Intraoperative bleeding
Time Frame: At the end of the surgery
Based on the amount of bleeding recorded during the surgery
At the end of the surgery
Conversion to laparotomy
Time Frame: At the end of the surgery
Based on intraoperative records to determine whether to convert to open laparotomy
At the end of the surgery
Duration of hepatic parenchymal transection
Time Frame: On the 7th day after surgery
Organize a dedicated person to review the surgical video and record the duration after the surgery is over
On the 7th day after surgery
Number of hemostatic clips used on the liver transection surface
Time Frame: On the 7th day after surgery
Organize a dedicated person to review the surgical video and record the duration after the surgery is over
On the 7th day after surgery
Tumor margins
Time Frame: At the end of the surgery
Specimen tumor margins will be measured by pathologists using calipers
At the end of the surgery
Postoperative complications
Time Frame: Up to 24 weeks after surgery
Organize a dedicated person to record postoperative complications
Up to 24 weeks after surgery
Postoperative hepatic function
Time Frame: Up to 4 weeks after surgery
Regularly measure liver function, coagulation, and other biochemical indicators after surgery after the patient returned to the ward
Up to 4 weeks after surgery
Postoperative bowel function recovery time
Time Frame: Up to 2 weeks after surgery
Organize a dedicated person to record the time of rectal gas passage after surgery afer he patient returned to the ward
Up to 2 weeks after surgery
Postoperative hospital stay
Time Frame: On the second day after discharge
Organize a dedicated person to record the postoperative hospital stay
On the second day after discharge

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival
Time Frame: From date of randomization until death or loss to follow-up, up to 5 years
Post-discharge follow-up (once every 3 months) using the follow-up center function of the professional EDC data management software to record follow-up via WeChat, questionnaires, and telephone calls
From date of randomization until death or loss to follow-up, up to 5 years
Disease-free survival
Time Frame: From the surgery was completed until disease progression or loss to follow-up, assessed up to 5 years
Post-discharge follow-up (once every 3 months) using the follow-up center function of the professional EDC data management software to record follow-up via WeChat, questionnaires, and telephone calls
From the surgery was completed until disease progression or loss to follow-up, assessed up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

West China Hospital

Collaborators

Nanjing Chia-Tai Tianqing Pharmaceutical Company

Investigators

  • Study Chair: Hong Wu, Professor, West China Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 10, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

December 25, 2023

First Submitted That Met QC Criteria

January 12, 2024

First Posted (Actual)

January 23, 2024

Study Record Updates

Last Update Posted (Actual)

January 23, 2024

Last Update Submitted That Met QC Criteria

January 12, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IHLAP2121

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Randomized Controlled Trial

Clinical Trials on NIF image-guided laparoscopic anatomical liver resection with the novel ICG@HSA administration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe